Metalloprotease inhibitor blocks angiotensin II-induced migration through inhibition of epidermal growth factor receptor transactivation

Biochemical and Biophysical Research Communications

Volumn 294, Issue 5, 2002, Pages 1023-1029

  Saito, Shuichi ^a   Frank, Gerald D ^a   Motley, Evangeline D ^b   Dempsey, Peter J ^c   Utsunomiya, Hirotoshi ^d   Inagami, Tadashi ^a   Eguchi, Satoru ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEHARRY MEDICAL COLLEGE   (United States)

^c PACIFIC NORTHWEST RESEARCH INSTITUTE   (United States)

^d WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Angiotensin II; EGF receptor; Metalloprotease; Migration; Vascular smooth muscle cell

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; [(4 BIPHENYLSULFONYL)AMINO] N HYDROXY 3 PHENYLPROPINAMIDE; ANGIOTENSIN; CALCIMYCIN; CALCIUM ION; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GELATINASE A; GELATINASE B; HYDROXAMIC ACID DERIVATIVE; MATRIX METALLOPROTEINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CELL GROWTH; CELL MIGRATION; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; DRUG SCREENING; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RAT; RECEPTOR UPREGULATION; SMOOTH MUSCLE FIBER; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE;

ANGIOTENSIN II; ANIMALS; CELL DIVISION; CELL MOVEMENT; CELLS, CULTURED; HYDROXAMIC ACIDS; MALE; MATRIX METALLOPROTEINASES; MITOGEN-ACTIVATED PROTEIN KINASES; MUSCLE, SMOOTH, VASCULAR; PROTEASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 0036289647     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-291X(02)00595-8     Document Type: Article

References (37)

1. Angiotensin receptors and their antagonists
2. Mechanism of protective effects of ACE inhibition on coronary artery disease
3. Angiotensin II receptor antagonists
4. The multiple actions of angiotensin II in atherosclerosis
5. Angiotensin II signaling in vascular smooth muscle. New concepts
6. Angiotensin II signal transduction in vascular smooth muscle: Pathways activated by specific tyrosine kinases
7. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells
8. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases
9. Calcium-dependent epidermal growth factor receptor transactivation mediates the angiotensin II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells
10. Epidermal growth factor receptor is indispensable for c-Fos expression and protein synthesis by angiotensin II
11. Signal transduction of angiotensin II type 1 receptor through receptor tyrosine kinase
12. 2+/calmodulin-dependent transactivation of epidermal growth factor receptor
13. N-acetylcysteine inhibits angiotensin II-mediated activation of extracellular signal-regulated kinase and epidermal growth factor receptor
14. Epidermal growth factor receptor transactivation by angiotensin II requires reactive oxygen species in vascular smooth muscle cells
15. Cell communication networks: Epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmission
16. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinases cleavage of proHB-EGF
17. Activation of MAPKs by angiotensin II in vascular smooth muscle cells
18. A metalloprotease-disintegrin MDC9/meltrin-g/AD-AM9 and PKCd are involved in TPA-induced ectodomain shedding of membrane-ancored heparin-binding EGF-like growth factor
19. Remarkable roles of proteolysis on and beyond the cell surface
20. Matrix metalloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specific juxtamembrane site
21. Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metalloproteinase inhibitor
22. Thrombin promotes activation of matrix metalloproteinase-2 produced by cultured vascular smooth muscle cells
23. Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells
24. eNOS gene transfer inhibits smooth muscle cell migration and MMP-2 and MMP-9 activity
25. Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives
26. 2+/calmodulin-sensitive tyrosine kinase
27. Regulatory effects of platelet-derived growth factor-AA homodimer on migration of vascular smooth muscle cells
28. Discovery of CGS27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits
29. Synthesis of a series of stromelysin-selective thiadiazole urea matrix metalloproteinase inhibitors
30. Metalloproteases and their inhibitors in matrix remodeling
31. Heparin blockade of thrombin-induced smooth muscle cell migration involves inhibition of epidermal growth factor (EGF) receptor transactivation by heparin-binding EGF-like growth factor
32. Metalloprotease-disintegrin MDC9: Intracellular maturation and catalytic activity
33. Ectodomain shedding of epidermal growth factor receptor ligands is required for keratinocyte migration in cutaneous wound healing
34. EGF-genistein inhibits neointimal hyperplasia after vascular injury in an experimental restenosis model
35. Central role of the MAPK pathway in AngII-mediated DNA synthesis and migration in rat vascular smooth muscle cells
36. The G-protein G13 but not G12 mediates signaling from lysophosphatidic acid receptor via epidermal growth factor receptor to Rho
37. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy